This story is part of, stories about the diverse teams that create products, apps and services to improve our lives and our society.
Pfizer’s and Moderna’s drugs are bothand most likely will be . Another vaccine developed by Oxford University and biotech company AstraZeneca has not yet proven as effective as the other two, . It’s likely that Oxford’s vaccine – as well as a handful of others not far behind it – will also seek FDA approval in the coming weeks and months. The Novavax vaccine, which some have called the most promising of the bunch, is currently on hold, but the company says it is still making progress with planned phase 3 clinical trials.
Pfizer expects, if authorized, to produce up to 50 million doses of vaccines by 2020 and 1.3 billion by 2021. Moderna plans to ship 20 million doses by 2020 and another 500 million to 1 billion by 2021, if permitted. With more than 330 million people in the US alone– The first doses to hit the market are likely to go to nursing home workers and residents, as well as primary health care workers, followed by essential workers, those with underlying medical conditions and older adults.
Currently, there are several dozen coronavirus vaccines in various stages of clinical trials, with a handful almost ready to apply for authorization. Most experts think we’ll have a few more ready to distribute in early 2021, but life may not start to return to normal until 2022.
Here we walk you through the top news about coronavirus vaccines and explain where the most promising candidates stand. This article is regularly updated and is intended as a general overview, not a source of medical advice. If you would like more information about coronavirus testing,.
Important news about COVID-19 vaccines
How many vaccines does the US need?
We probably won’t know until next year, but Fauci has suggested that we might need different vaccines created and distributed by different labs to end the pandemic, in an article published May 11 in the journal Science has been published. He has also said that he envisions that different vaccines will be given to different patient populations. For example, one vaccine for the elderly or other high-risk patients, another for healthy adults and another for children.
What if people don’t trust the vaccines?
Getting one or more vaccines through clinical trials to FDA approval is just the first part of the journey. The next thing is to convince people to take it. Sixty-three percent of U.S. adults expressed concerns about the safety of a coronavirus vaccine, according to an Oct. 19 Harris Poll, with 40% of respondents specifically concerned that the development is to fast. Some people are reported to be concerned about possible side effects.
Life in the US will return to normal if we achieve what scientists call “herd immunity,” which, with regard to the coronavirus, means that at least 60% to 70% of the population is immune. As long as enough people are taking the vaccine to reach that level, it doesn’t matter if a few people object or refuse to take the vaccine for other reasons, such as if they are not healthy enough to be vaccinated.
What to do until a coronavirus vaccine is approved?
Coronaviruses are a large class of viruses and so far there are none of these vaccines. While early results are promising, there is no guarantee that a vaccine will be ready by 2021. Statistically, only about 6% of vaccine candidates ever make it to the market, according to an April Reuters report. However, health officials are very optimistic that the Pfizer vaccine and similar vaccines can end the coronavirus pandemic.
Whether COVID-19 vaccines are effective in stopping the spread of coronavirus depends a lot on how our bodies build immunity to the disease. Here’s what we know so far about whether or not you can do it. Testing is also key to slowing the spread of the coronavirus – learn more about a device that can yield results in . Finally, read how all these issues and more weigh on US President-elect Joseph .
Other promising coronavirus vaccines around the world
Here’s a quick look at some of the front runners alongside Pfizer and Moderna in the race to find a vaccine for COVID-19, including where the vaccines are developed, where they test them, and when scientists think they might be ready for widespread distribution, if known.
Oxford University / AstraZeneca (UK): AstraZeneca began testing on 100,000 human volunteers in at least three countries. Lead investigator Dr. Sarah Gilbert had initially said AstraZeneca is aiming for a fall 2020 release and while that may be optimistic at this point after briefly pausing the process to investigate a participant’s disease, it does not appear to have slowed down significantly .
Sinovac (China): Currently, the vaccine is being tested on about 10,000 human volunteers in China and about 9,000 in Brazil, and will soon begin testing on about 1,900 subjects in Indonesia. Honesti Basyir, the president of Bio Farma, Sinovac’s Indonesian partner, has said he expects the vaccine to be ready in early 2021.
Sinopharm (China): Currently, about 15,000 volunteers in the Middle East are being tested in a trial that the state-owned company expects to take three to six months. Initial results suggest the drug is safe and at least somewhat effective. Sinopharm recently built a second facility to produce the vaccine, doubling its capacity to approximately 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine, which will begin large-scale human trials this summer, has already been approved by the Chinese military. The vaccine is based on a modified cold virus, which some experts warn could make it less effective than other vaccination efforts.
The development of the COVID-19 vaccine is very fast
Several acceleration efforts are currently underway, such as the White House’s Operation Warp Speed, which aims to cut the red tape to accelerate vaccine development and be ready to distribute vaccines once they are approved by the FDA. So far, the US government has pledged more than $ 10 billion to several vaccine manufacturers to secure a total of 800 million vaccine doses.
Vaccines typically take about 10 to 15 years to develop and approve, through four phases, including human trials. But with Operation Warp Speed, approved vaccine projects can send data to the FDA little by little, instead of submitting all of the data from a four-phase trial at once.
Meanwhile, the program also supports financial efforts to start manufacturing doses while clinical trials are ongoing. That means that if and when those vaccines are authorized, there will already be a supply of doses that can be distributed nationally.
The information in this article is for educational and informational purposes only and is not intended to be health or medical advice. Always consult a physician or other qualified health care practitioner if you have any questions about a medical condition or health goals.